This naturalistic, retrospective study investigated the effects of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD) symptoms and autistic features in children with autism spectrum disorders (ASDs) and intellectual disability (ID).
Methods:
Participants (n = 37, age range 6–17 years, mean: 10.16 ± 3.60) were assessed at baseline, 4th and 12th weeks using Clinical Global Impressions (CGI) scales, DSM-IV-based ADHD-rating scale (ADHD-RS), and amended Turkish version of Aberrant Behavior Checklist (ABC). The primary outcome measure was a treatment response defined by a CGI-improvement score of 1 or 2 together with a decrease of at least 25% in the parent-rated ADHD-RS total score at the end of 12th week.
Results:
Five patients (13.5%) stopped medication at 4 weeks due to ineffectivity (2) and intolerable side effects (increased motor activity and talkativeness [n = 1], irritability [n = 2], temper outbursts [n = 2], and increased blood pressure [n = 1]). Sixteen patients (43.2%) were judged to be responders according to primary outcome measure. Improvement rate on CGI scale was 48.8%. On ADHD-RS, there were significant reductions between baseline and 4th week and between baseline and 12th week in both hyperactivity and inattention, and between baseline and 12th week in impulsivity scores. Decrease was significant in hyperactivity and social withdrawal subscales of the parent-reported ABC. Responders based on primary outcome measure were not significantly different from nonresponders in terms of sociodemographic features or clinical parameters, including intellectual, language, autism symptom, and ADHD symptom levels.
Conclusion:
In this chart review, ATX appears to be safe and effective for social withdrawal and ADHD symptoms in children with ASD and ID.
Get full access to this article
View all access options for this article.
References
1.
AmanMG, FarmerCA, HollwayJ, ArnoldLE: Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am, 17:713–738, 2008.
2.
AmanMG, SinghNN, StewartAW, FieldCJ: The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic, 89:485–491, 1985.
3.
AmanMG, SmithT, ArnoldLE, Corbett-DickP, TumuluruR, HollwayJA, HymanSL, Mendoza-BurchamM, PanX, MruzekDW, LecavalierL, LevatoL, SilvermanLB, HandenB: A review of atomoxetine effects in young people with developmental disabilities. Res Dev Disabil, 35:1412–1424, 2014.
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
5.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
6.
ArnoldLE, AmanMG, CookAM, WitwerAN, HallKL, ThompsonS, RamadanY: Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry, 45:1196–1205, 2006.
7.
BarkleyRA, McMurrayMB, EdelbrockCS, RobbinsK: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics, 86:184–192, 1990.
8.
CharnsilC: Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: An open-label study. J Atten Disord, 15:684–689, 2011.
9.
CohenJ: Statistical Power Analysis for the Behavioral Sciences, 2 ed. Hillsdale (New Jersey), Lawrence Erlbaum Associates, 1988.
10.
DalsgaardS, NielsenHS, SimonsenM: Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A Danish register-based study. J Child Adolesc Psychopharmacol, 23:432–439, 2013.
11.
DuPaulGJ, PowerTJ, AnastopoulosAD, ReidR: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, Guilford Press, 1998.
12.
El AchkarCM, SpenceSJ: Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy. Epilepsy Behav, 47:183–190, 2015.
13.
Fernandez-JaenA, Fernandez-MayoralasDM, Calleja-PerezB, Munoz-JarenoN, Campos Diaz MdelR, Lopez-ArribasS: Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: A prospective, open-label study. J Atten Disord, 17:497–505, 2013.
14.
GadowKD, DeVincentCJ, PomeroyJ: ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord, 36:271–283, 2006.
15.
GuyW: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville (Maryland), United States Department of Health, Education and Welfare, 1976.
16.
HarfterkampM, BuitelaarJK, MinderaaRB, van de Loo-NeusG, van der GaagRJ, HoekstraPJ: Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: An open-label extension study. J Child Adolesc Psychopharmacol, 23:194–199, 2013.
17.
HarfterkampM, BuitelaarJK, MinderaaRB, van de Loo-NeusG, van der GaagRJ, HoekstraPJ: Atomoxetine in autism spectrum disorder: No effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. J Child Adolesc, Psychopharmacol24:481–485, 2014.
18.
HarfterkampM, van de Loo-NeusG, MinderaaRB, van der GaagRJ, EscobarR, SchachtA, PamulapatiS, BuitelaarJK, HoekstraPJ: A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry, 51:733–741, 2012.
19.
HarfterkampM, van der MeerD, van der Loo-NeusG, BuitelaarJK, MinderaaRB, HoekstraPJ: No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder. J Child Adolesc Psychopharmacol, 25:372–375, 2015.
20.
HoltmannM, BolteS, PoustkaF: Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: Association with autistic behavior domains and coexisting psychopathology. Psychopathology, 40:172–177, 2007.
21.
JouRJ, HandenBL, HardanAY: Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 15:325–330, 2005.
22.
KratochvilCJ, MiltonDR, VaughanBS, GreenhillLL: Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health, 2:25, 2008.
23.
LordC, RisiS, LambrechtL, CookEHJr., LeventhalBL, DiLavorePC, PicklesA, RutterM: The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord, 30:205–223, 2000.
24.
LordC, RutterM, CouteurAL: Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord, 24:659–685, 1994.
25.
MazzoneL, RealeL, ManninoV, CocuzzaM, VitielloB: Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs, 25:503–509, 2011.
26.
MurrayM: Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatry Rep, 123:382–388, 2010.
27.
OswaldDP, SonenklarNA: Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol, 17:348–355, 2007.
PrakashA, RisserRC, MallinckrodtCH: The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract, 62:1147–1158, 2008.
30.
ReichowB, VolkmarFR, BlochMH: Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord, 43:2435–2441, 2013.
SchwartzS, CorrellCU: Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry, 53:174–187, 2014.
33.
ShibaoC, RajSR, GamboaA, DiedrichA, ChoiL, BlackBK, RobertsonD, BiaggioniI: Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension, 50:47–53, 2007.
34.
StreinerD, GeddesJ: Intention to treat analysis in clinical trials when there are missing data. Evid Based Ment Health, 4:70–71, 2001.
35.
SucuogluB: The psychometric characteristics of the Turkish form of the aberrant behavior checklist. Turkish J Psychol, 18:93–96, 2003.
36.
SucuogluB, OktemF, AkkokF, GoklerB: A study of the scales for the assessment of the children with autism. J Psychiatry Psychopharmacol Psychol, 4:116–121, 1996.
TroostPW, SteenhuisMP, Tuynman-QuaHG, KalverdijkLJ, BuitelaarJK, MinderaaRB, HoekstraPJ: Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol, 16:611–619, 2006.
39.
WechslerD: Wechsler Intelligence Scale for Children–Revised. New York, Psychological Corporation, 1974.
40.
YerysBE, WallaceGL, SokoloffJL, ShookDA, JamesJD, KenworthyL: Attention deficit/hyperactivity disorder symptoms moderate cognition and behavior in children with autism spectrum disorders. Autism Res, 2:322–333, 2009.
41.
ZeinerP, GjevikE, WeidleB: Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr, 100:1258–1261, 2011.
